Option Care Health (OPCH) Q2 2024 earnings summary

Executive summary

• Q2 2024 net revenue increased 14.8% year-over-year to $1.23 billion, driven by balanced growth in acute and chronic therapies, with strong contributions from new limited distribution and rare/orphan therapies.

• Net income for Q2 2024 was $53.0 million, down 53.6% from Q2 2023 due to the absence of a prior-year one-time Amedisys merger termination payment.

• Successfully navigated significant challenges, including a major cyberattack and supply chain disruptions, with operational recovery largely completed by quarter-end and claims processing restored.

• Maintained uninterrupted patient onboarding and service, leveraging innovative workarounds and process modifications.

• Reengaged capital deployment, repurchasing $78 million in stock during the quarter as cash flow and balance sheet strength improved.

Financial highlights

• Gross profit was $249.4 million (20.3% margin), slightly down from $250.8 million (23.5% margin) in Q2 2023, with normalized year-over-year growth of about 3%.

• Adjusted EBITDA reached $108.4 million, down 1.5% year-over-year but up $10 million sequentially, representing 8.8% of revenue.

• Earnings per share was $0.30, benefiting from share repurchases.

• Generated $195.7 million in operating cash flow in Q2 and reduced accounts receivable by over $100 million.

• SG&A expenses were flat, with SG&A as a percent of revenue dropping to a record low of 12.5%.

Outlook and guidance

• Increased full-year revenue guidance to $4.75–$4.85 billion and Adjusted EBITDA guidance to $435–$450 million.

• Expect to generate at least $300 million in operating cash flow for the year.

• Anticipate some lingering inefficiencies in Q3 as recovery from the cyberattack is finalized.

• Effective tax rate projected at 26%-28%; net interest expense forecasted at $55–$60 million.